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groups. ConClusions: A greater number of T2D respondents were not adherent 
to their diabetes medication. Not surprisingly, health outcomes were worse among 
adults not adhering to their medications.
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objeCtives: To study prescription pattern, calculate the cost of antidiabetic drugs 
and to evaluate the adherence to treatment guidelines in diabetic patients attending 
the medicine outpatient department in a tertiary care teaching hospital. Methods: 
A prospective observational study was carried out for a period of 5 months. The 
diabetic patients who visited the medicine outdoor department were included. 
Demographic data and complete prescription details were recorded in the struc-
tured case record form. Cost of the drug therapy was calculated from the patient’s 
bills. Indian Council for Medical research guidelines-2005 for diabetes management 
was used to evaluate the adherence. Results: A total of 250 patients were enrolled 
in the study with mean age 57.91 ± 9.37. Out of 250 patients 126 (50.4%) were male 
and rest were female. A total of 1,391 drugs were prescribed, with mean of 5.56 ± 
2.52 drugs and out of which 539 drugs were antidiabetics with mean of 2.18 ± 0.96. 
In monotherapy, metformin was frequently 218 (40.45%) prescribed. Glimepiride 
and metformin was the most frequently prescribed in 119 (76.28%) out of 156 anti-
diabetic drug combinations. Most commonly used drugs other than antidiabetics 
were aspirin 146 (18.9%) and atorvastatin 119 (15.41%). Mean cost of therapy for a 
month for a diabetic patient was 354.60 ± 305.72 INR. Majority 209 (83.6%) of pre-
scriptions was in accordance to guidelines. ConClusions: Metformin was the 
most frequently prescribed drug in the diabetes patient. Metformin and glimepiride 
being the most frequent combination used. Majority of the prescriptions followed 
standard guidelines. The cost of prescription can be reduced by choosing the most 
economic drugs (generic) without changing its quality.
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objeCtives: To evaluate the impact of home medication review programme 
(HMR) towards Type 2 Diabetes patients from public primary centre in Penang, 
Malaysia. Methods: A prospective randomised control study was conducted 
at Primary Clinic in Bukit Minyak, Penang. Eligible Type 2 diabetes patients with 
HbA1c > 6.5% and taking ≥ 3 medications who stayed at their own house were 
recruited and randomly allocated into control and intervention group by coin toss-
ing. Control group patients received usual care from the clinic whereas intervention 
group patients received additional 2 visits at their home by pharmacist. During 
both visits, education on quality use of medications and life-style modifications 
were performed.Blood pressure monitoring, point of care for sugar and total cho-
lesterol levels were conducted in each visit. Patients adherence and knowledge 
were assessed using validated questionnaire. Pill count was conducted and exces-
sive medications were collected to calculate the costing component. Primary out-
comes were medication adherence and level of knowledge. Secondary outcomes 
included HbA1c, FBS and total cholesterol changes as well as patients’ satisfactions 
towards HMR and direct cost saving from the programme. Results: A total of 150 
patients were recruited and randomly assigned in two groups (n= 75 each group). 
Fifty patients in the intervention group completed the study. After 2 home visits 
there were significant improvements in the adherence score for the intervention 
group (mean score= 6.90,SD= 0.94) compared to the control group (mean score= 4.05, 
SD= 1.51). There was a significant improvement in knowledge score after HMR pro-
gramme, intervention group (mean score= 10.04, SD= 1.75) and the control group 
(mean score= 5.45, SD= 1.89). A direct cost analysis of the medication wasted reveals 
that HMR can help to save RM 2805.50 (USD 855.34) throughout the eight months 
period. ConClusions: Pharmacist-led HMR have improved patients’ adherence 
and knowledge as well as helping the policy makers to save money on excessive 
medication wastage.
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objeCtives: To compare the time trade-off (TTO) values of EQ-5D-3L health states 
elicited from Asians with and without type 2 diabetes mellitus (T2DM) and T2DM 
patients with and without complications in Singapore. Methods: The TTO values 
of 10 EQ-5D-3L health states were elicited from a consecutive sample of T2DM 
patients and a general Singaporean population sample using an identical valu-
ation protocol. In face-to-face interviews, T2DM patients and members of the 
general population were asked to value 5 and 10 health states, respectively. The 
difference in TTO values between the two samples and between T2DM patients 
with and without complications was examined using multiple linear regression 
models. Results: A total of 109 T2DM patients and 46 persons without T2DM 
provided data for this study. All 10 health states considered, the mean TTO value 
was 0.04 for T2DM patients and -0.02 for the general population sample, with the 
difference (95% confidence interval [95%CI]) being -0.06 (-0.16, 0.03). The general 
population sample had systematically lower TTO values for mild health states, 
with the difference being -0.15 (95%CI: -0.24, -0.06); while the two samples had 
similar mean TTO values for severe health states, with the difference being 0.001 
predict quality of life utilities, diabetes complications and mortality. Methods: 
A microsimulation model was constructed which followed people with newly 
diagnosed diabetes over a period of 10 years. HbA1c level determined when a per-
son was assumed to undergo escalation in diabetic treatment (from monotherapy 
with non-insulin hypoglycaemics to dual therapy to triple therapy and insulin). 
Information on efficacy and toxicity of therapies were derived from clinical trial 
data. Health care utilisation and costs were sourced from Australian government 
websites. Risk equations using change in HbA1c as a predictor for complications, 
quality-adjusted life years (QALYs) and death were derived from published data 
from large Australian diabetes cohorts. Probabilistic sensitivity analyses were under-
taken. Two classes of drugs were investigated as alternatives to sulphonylurea when 
given in combination with metformin: DPP-IV inhibitors (sitagliptin, vildagliptin, 
saxagliptin, linagliptin, alogliptin) and SGLT-2 inhibitors (canagliflozin, dapagliflo-
zin). Results: In general, the results for the CUA were similar between the two 
drug classes compared to sulphonylureas, with ICERs ranging from AU$40K/QALY 
to AU$50K/QALY. The proportion of diabetes complications dropped by 3-4%, insulin 
treatment was delayed on an average of 2-3 years and a drop of 1-2% in mortality 
was observed. ConClusions: This model illustrates a new way of assessing the 
cost utility of diabetes medications. Furthermore, it shows that both DPP-IV and 
SGLT-2 inhibitors represent cost-effective alternatives to sulphonylurea in combi-
nation with metformin.
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objeCtives: In China, the age-standardized prevalence of diabetes is 9.7% (92.4 
million adults). The rapidly-growing economic burden caused by diabetes renders 
the anti-diabetic drug utilization research more important than ever. This study 
intends to assess the utilization and its dynamic trends of anti-diabetic drugs in a 
tertiary hospital in Beijing, China. Methods: Data were extracted from pharmacy 
department of a tertiary hospital in Beijing between 2008 and 2012. Descriptive 
analysis was conducted using SPSS 20. By applying the Anatomical-Therapeutic-
Chemical methodology (ATC) and Defined Daily Dose system (DDD) recommended 
by WHO, the collected data were used to calculate the number DDD per 1000 inhabit-
ants per day (DDD/1000/day). Annual average growth rate (AAGR) was calculated to 
demonstrate dynamic trends in utilizations over time. Results: There are three 
major findings: 1) By pooling the five year data together, we found the top three 
drug categories were sulfonylureas (3032.87 DDD/1000/day), human insulin (2677.48 
DDD/1000/day) and biguanides (1830.52 DDD/1000/day), accounting for 30.95%, 
27.32% and 18.68% of the total DDDs, respectively. 2) In each category, the rankings 
in utilization according to DDD were gliclazide, glimepiride, gliquidone for sulfo-
nylureas, and Novolin 30R, Novolin R, humulin for human insulin, and metformin 
for biguanides. 3) Drug utilizations increased rapidly from 1647.13 DDD/1000/day in 
2008 to 9798.86 DDD/1000/day in 2012, with AAGR of 13.41%. The utilization of insulin 
analogue increased fastest (AAGR 33.21%), followed by glinides (AAGR 27.18%) and 
biguanides (AAGR 20.77%). ConClusions: In a tertiary hospital in Beijing, the total 
DDD of anti-diabetic drugs was largely contributed by sulfonylureas, human insulin 
and biguanides, in descending order. Utilization of anti-diabetic drugs increased 
significantly during 2008-2012, possibly driven by increasing prevalence, new treat-
ments, and so forth.
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objeCtives: Adherence to treatment is an important predictor of health status. 
This study investigated medication adherence among respondents with type 2 
diabetes (T2D) in China. Methods: This study included data from the 2013 China 
(N= 19,987) National Health and Wellness Survey (NHWS), a cross-sectional survey of 
self-reported demographics, health outcomes, and behaviors among urban (mainly 
Tier I and II cities) adults (≥ 18 years). Respondents diagnosed with T2D and taking a 
prescription medication for T2D were analyzed (n= 510). Adherence was measured 
using the 8-item Morisky Medication Adherence Scale (MMAS). Adherence was 
classified as scoring between 0-2 on the MMAS. Characteristics of non-adherent 
and adherent respondents were reported descriptively. Multivariable regressions, 
adjusting for demographics and health behaviors were performed to explore dif-
ferences on health status (SF-36v2), resource utilization in the past six months 
and productivity loss (Work Productivity and Activity Impairment questionnaire) 
between adherent (n= 184) and non-adherent respondent groups (n= 326). Results: 
Respondents who were non- adherent to diabetes medications tended to be younger, 
employed and had regular consumption of alcohol when compared to respondents 
who were adherent. Controlling for covariates, respondents who were adherent to 
their medications had higher mental component summary and health utility scores 
compared to non-adherent respondents (p< 0.05). Among the employed sample, 
non-adherent respondents reported greater absenteeism (13.1% vs. 7.7%), greater 
presenteeism (39.8% vs. 30.9%), and greater overall work impairment (44.8% vs. 
33.7%) compared to adherent respondents. Non-adherent vs. adherent respond-
ents reported more activity impairment (38.8% vs. 33.7%). Physician visits in the 
past six months was higher among those who were not adherent (6.0 vs. 4.6), but 
there was no significant difference in hospitalization and ER visits among the two 
